This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Q4 Biotech Earnings Preview

By: Adam Feuerstein | 01/27/14 - 06:50 AM EST

Here's a cheat sheet for the biotech companies reporting fourth-quarter earnings -- and providing 2014 financial guidance -- this week.

Amgen (AMGN): Jan. 28 after the close

Q4 consensus:
Adjusted EPS: $1.68
Total revenue: $4.82 billion 

Key product sales consensus:
Epogen/Aranesp worldwide: $949 million
Neupogen/Neulasta worldwide: $1.4 billion 
Enbrel worldwide: $1.2 billion 
Kyprolis: $72 million

2014 consensus:
Adjusted EPS: $8.14
Total revenue: $19.58 billion.

Key questions/issues: Biosimilar threat to base business (EPO and filgrastim) sales, evolocumab (PCSK9) clinical/regulatory update.

Biogen Idec (BIIB): Jan. 29 before the open

Q4 consensus:
Adjusted EPS: $2.27
Total revenue: $1.93 billion

Key product sales consensus:
Avonex worldwide: $725 million
Tysabri: $483 million
Tecfidera: $344 million

2014 consensus:
Adjusted EPS: $11.62
Total revenue: $8.35 billion.

Key questions/issues: Discussion of Tecfidera European launch, preparations for hemophilia product launch, pipeline update.

Vertex Pharmaceuticals (VRTX): Jan. 29 after the close

Q4 consensus:
Adjusted EPS: ($0.28)
Total revenue: $234 million

2014 consensus:
Adjusted EPS: ($1.80)
Total revenue: $678.4 million

Key questions/issues: Update on Kalydeco/VX-809 phase III studies and development of fixed-dose pill.

Celgene (CELG): Jan. 30 before the open. [Celgene pre-announced earnings and provdeded guidance on Jan. 13.]

Q4 consensus:
Adjusted EPS: $1.55
Total revenue: $1.713 billion

Key product sales consensus:
Revlimid worldwide: $1.14 billion.
Abraxane: $195 million
Pomalyst: $120 million

2014 consensus:
Adjusted EPS: $7.24
Total revenue: $7.49 billion.

Key questions/issues: Update on Revlimid frontline multiple myeloma regulatory filing and discussion of commercial launch of Otezla (apremilast) in the U.S.

Alexion Pharmaceuticals (ALXN): Jan. 30 before the open

Q4 consensus:
Adjusted EPS: 0.84
Total revenue: $432 million

2014 consensus:
Adjusted EPS: $3.41
Total revenue: $1.95 billion.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 16,940.59 -143.21 -0.84%
S&P 500 1,981.67 -6.31 -0.32%
NASDAQ 4,452.2090 -19.8990 -0.44%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs